Vanta Bioscience Limited
BSE: VANTABIO
Prev Close
24.26
Open Price
23.05
Volume
750
Today Low / High
23.05 / 23.05
52 WK Low / High
19.08 / 44.49
Range
22 - 24
The stock is currently available for trading on the Bombay Stock Exchange (BSE). Its price is 23.05, reflecting a change of -1.21 (-4.98763%). The expected target range on the BSE is 22 - 24. The stock is showing a downward trend on the BSE. This could indicate a potential risk for investors who are considering buying at this moment.
Vanta Bioscience Limited Graph
Vanta Bioscience Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Vanta Bioscience Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 23.05, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 23.05 | 23.28 | 20.95 - 25.61 |
| 23.51 | 18.81 - 28.21 | ||
| 23.74 | 16.62 - 30.86 | ||
| Bearish Scenario | 23.05 | 22.82 | 20.54 - 25.10 |
| 22.59 | 18.07 - 27.11 | ||
| 22.36 | 15.65 - 29.07 |
Overview of Vanta Bioscience Limited
ISIN
INE695X01011
Industry
Biotechnology
Vol.Avg
3,463
Market Cap
145,580,504
Last Dividend
0
Official Website
IPO Date
2017-10-06
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1.96 Cr | 1.34 Cr | 0.63 Cr | 0.3201 | 0.00 Cr | 0.00 Cr | -8.67 Cr | -4.77 Cr | -7.56 | -4.15 Cr | -2.4317 |
| 2024-03-31 | 9.72 Cr | 9.01 Cr | 0.71 Cr | 0.0732 | 0.00 Cr | 5.00 Cr | -3.18 Cr | -2.32 Cr | -3.67 | 1.42 Cr | -0.2382 |
| 2023-03-31 | 5.83 Cr | 7.16 Cr | -1.33 Cr | -0.2288 | 0.00 Cr | 0.77 Cr | -5.06 Cr | -6.48 Cr | -10.27 | -1.71 Cr | -1.1118 |
| 2022-03-31 | 9.39 Cr | 4.80 Cr | 4.60 Cr | 0.4893 | 0.00 Cr | 0.26 Cr | 2.15 Cr | 0.09 Cr | 0.14 | 3.89 Cr | 0.0094 |
| 2021-03-31 | 9.82 Cr | 4.66 Cr | 5.15 Cr | 0.5251 | 0.00 Cr | 0.26 Cr | 2.75 Cr | 0.45 Cr | 0.71 | 3.97 Cr | 0.0458 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.22 Cr | 85.88 Cr | 82.10 Cr | 10.4240 Cr | 70.08 Cr | 69.86 Cr | 6.51 Cr | 23.96 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 26.5643 Cr |
| 2024-03-31 | 0.16 Cr | 85.40 Cr | 72.42 Cr | 15.1989 Cr | 60.95 Cr | 60.79 Cr | 7.52 Cr | 28.41 Cr | 0.00 Cr | 0.00 Cr | 0.91 Cr | 22.8768 Cr |
| 2023-03-31 | 0.10 Cr | 84.71 Cr | 65.78 Cr | 17.5147 Cr | 57.16 Cr | 57.06 Cr | 7.16 Cr | 33.23 Cr | 0.00 Cr | 0.00 Cr | 0.91 Cr | 17.7470 Cr |
| 2022-03-31 | 0.22 Cr | 81.40 Cr | 52.06 Cr | 24.0070 Cr | 44.87 Cr | 44.64 Cr | 7.24 Cr | 37.32 Cr | 0.04 Cr | 0.00 Cr | 1.42 Cr | 14.2785 Cr |
| 2021-03-31 | 2.65 Cr | 69.63 Cr | 43.40 Cr | 23.9188 Cr | 35.97 Cr | 33.32 Cr | 9.76 Cr | 34.86 Cr | 0.06 Cr | 0.00 Cr | 0.00 Cr | 14.8431 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -2.4086 Cr | -6.6935 Cr | 9.1631 Cr | -9.1021 Cr | 0.0610 Cr | 0.2216 Cr | -6.6935 Cr | -12.6289 Cr | 9.1305 Cr | 0.0000 Cr | 1.0135 Cr |
| 2024-03-31 | 2.6840 Cr | -3.3132 Cr | 0.6932 Cr | -0.7207 Cr | 0.0640 Cr | 0.1606 Cr | -3.4047 Cr | -8.8266 Cr | 3.7921 Cr | 0.0000 Cr | -0.3630 Cr |
| 2023-03-31 | -6.5135 Cr | -5.9087 Cr | 12.2946 Cr | -35.2025 Cr | -0.1276 Cr | 0.0966 Cr | -28.6890 Cr | -6.4807 Cr | 12.2946 Cr | 0.0000 Cr | 0.0780 Cr |
| 2022-03-31 | 2.8753 Cr | -17.1807 Cr | 11.8793 Cr | -14.3054 Cr | -2.4261 Cr | 0.2242 Cr | -17.1807 Cr | 0.0882 Cr | 8.8970 Cr | 0.0000 Cr | 2.5287 Cr |
| 2021-03-31 | 4.7291 Cr | -22.1943 Cr | 19.9204 Cr | -17.4652 Cr | 2.4552 Cr | 2.6503 Cr | -22.1943 Cr | 0.4495 Cr | 18.6004 Cr | 0.0000 Cr | 4.2431 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.45 Cr | 1.32 Cr | -0.87 Cr | -1.9464 | -1.24 Cr | -1.35 Cr | -2.14 | -1.96 Cr | -3.0293 |
| 2024-12-31 | 0.45 Cr | 1.32 Cr | -0.87 Cr | -1.9464 | -1.24 Cr | -1.35 Cr | -2.14 | -1.96 Cr | -3.0293 |
| 2024-09-30 | 1.03 Cr | 1.70 Cr | -0.67 Cr | -0.6534 | -2.07 Cr | -2.07 Cr | -3.28 | -0.34 Cr | -2.0076 |
| 2024-06-30 | 0.54 Cr | 0.65 Cr | 1.18 Cr | 2.2118 | -0.77 Cr | -1.03 Cr | -1.64 | -0.17 Cr | -1.9329 |
| 2024-03-31 | 3.55 Cr | 4.99 Cr | -1.44 Cr | -0.4069 | -3.70 Cr | -1.78 Cr | -2.82 | -0.67 Cr | -0.5017 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 0.22 Cr | 0.00 Cr | 0.22 Cr | 8.13 Cr | 6.51 Cr | 15.36 Cr | 23.96 Cr | 85.88 Cr | 82.10 Cr |
| 2024-12-31 | 0.22 Cr | 0.00 Cr | 0.22 Cr | 2.50 Cr | 6.51 Cr | 15.36 Cr | 23.96 Cr | 85.88 Cr | 82.10 Cr |
| 2024-09-30 | 0.16 Cr | 0.00 Cr | 0.16 Cr | 2.44 Cr | 9.02 Cr | 17.46 Cr | 26.31 Cr | 85.65 Cr | 76.30 Cr |
| 2024-06-30 | 0.16 Cr | 0.00 Cr | 0.16 Cr | 2.44 Cr | 9.02 Cr | 17.46 Cr | 26.31 Cr | 85.65 Cr | 76.30 Cr |
| 2024-03-31 | 0.16 Cr | 0.00 Cr | 0.16 Cr | 8.92 Cr | 7.52 Cr | 17.16 Cr | 28.41 Cr | 85.40 Cr | 72.42 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | -1.35 Cr | -2.74 Cr | -5.07 Cr | 7.86 Cr | 0.06 Cr | 0.22 Cr | 0.16 Cr | -2.53 Cr | -2.94 Cr |
| 2024-12-31 | -1.35 Cr | -0.41 Cr | -2.53 Cr | 2.97 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2.53 Cr | -2.94 Cr |
| 2024-09-30 | -2.07 Cr | -3.74 Cr | -1.63 Cr | 5.37 Cr | 0.00 Cr | 0.16 Cr | 0.16 Cr | -1.63 Cr | -5.36 Cr |
| 2024-06-30 | -1.03 Cr | -0.80 Cr | -0.81 Cr | 1.61 Cr | 0.00 Cr | 0.16 Cr | 0.16 Cr | -0.81 Cr | -1.61 Cr |
| 2024-03-31 | -1.78 Cr | -2.36 Cr | -1.67 Cr | 3.84 Cr | 0.02 Cr | 0.16 Cr | 0.14 Cr | -1.76 Cr | -3.94 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹351.00 | ₹468,432,435,042.00 | ₹2,267,842.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹197.73 | ₹261,823,998,973.00 | ₹1,975,379.00 |
| Syngene International Limited | SYNGENE | ₹632.55 | ₹253,895,691,467.00 | ₹303,056.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,603.00 | ₹167,699,775,012.00 | ₹38,207.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹664.50 | ₹115,267,774,913.00 | ₹468,988.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹666.55 | ₹105,405,727,436.00 | ₹151,201.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹732.60 | ₹58,961,699,280.00 | ₹162,531.00 |
| Zota Health Care Limited | ZOTA | ₹1,485.10 | ₹45,047,025,941.00 | ₹50,126.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹283.20 | ₹44,400,972,504.00 | ₹117,658.00 |
Key Executives
Gender: male
Year Born: 1966
Gender: female
Year Born:
Gender: male
Year Born: 1985
Gender: male
Year Born:
FAQs about Vanta Bioscience Limited
The CEO is Dopesh Raja Mulakala.
The current price is ₹23.05.
The range is ₹19.08-44.49.
The market capitalization is ₹14.56 crores.
The P/E ratio is -2.51.
The company operates in the Healthcare sector.
Overview of Vanta Bioscience Limited (ISIN: INE695X01011) is a leading Biotechnology in India. With a market capitalization of ₹14.56 crores and an average daily volume of 3,463 shares, it operates in the Biotechnology. The company last declared a dividend of ₹0.